Hideaki Kishimoto
Tottori, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.
Journal: Journal of bone and mineral metabolism
Published: February 27, 2019
A randomized, double-blind, placebo-controlled study of once weekly elcatonin in primary postmenopausal osteoporosis.
Journal: Current medical research and opinion
Published: July 11, 2018
Erratum to: Attempt at standardization of bone quantitative ultrasound in Japan.
Journal: Journal of medical ultrasonics (2001)
Published: September 22, 2017
Attempt at standardization of bone quantitative ultrasound in Japan.
Journal: Journal of medical ultrasonics (2001)
Published: May 11, 2017
24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk.
Journal: Advances in therapy
Published: April 27, 2017
Effects of antiresorptive therapy on the structural and material properties of bone strength
Journal: Clinical calcium
Published: January 06, 2016
Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA.
Journal: Archives of osteoporosis
Published: March 30, 2015
Effects of aging and therapy on the structural properties and strength of vertebral body
Journal: Clinical calcium
Published: July 02, 2013
Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Journal: Journal of bone and mineral metabolism
Published: May 01, 2013
Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Journal: Current medical research and opinion
Published: December 25, 2012
Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 23, 2012
Last Updated: 09/26/2026